pH Pharma IND approval for “Alpha-1 Antitrypsin Deficiency treatment” Phase 2 clinical trial in Europe

PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.

(For more information, please refer to the link below)

https://www.edaily.co.kr/news/read?newsId=02745366625637392